#USA #Nashville #Phagenesis #Phagenyx #Stephen Oesterle

Phagenesis Enhances Leadership with Dr. Stephen Oesterle

In a significant step toward amplifying its impact in the medical technology sector, Phagenesis recently announced the appointment of Dr. Stephen N. Oesterle to its Board of Directors. As a pioneering company specializing in neuromodulation therapies for swallowing disorders, Phagenesis is poised for its next phase of growth, particularly as it looks to expand its footprint in both the U.S. and global markets.

Experienced Leadership for Vital Growth

Dr. Oesterle brings an impressive track record with decades of experience in the medical technology and life sciences industries. His past role as Senior Vice President for Medicine and Technology at Medtronic saw him contribute significantly to corporate strategies and innovations over the span of fourteen years. His invaluable insights into the complexities of clinical medicine and corporate strategy make him an outstanding addition to the Phagenesis Board.

A Strategic Vision for Phagenesis

Oern Stuge, MD, MBA, Chairman of the Board for Phagenesis, expressed enthusiasm about Dr. Oesterle's addition, highlighting his experience and understanding of the medical technology landscape. “Steve brings deep experience across several applications within medical technology, supported by a history of guiding companies through crucial growth stages,” said Dr. Stuge. The board leadership believes that Dr. Oesterle will play a critical role in fortifying the company’s ongoing mission to develop leading-edge solutions for sorely needed patient care.

Commitment to Patients and Healthcare Systems

Upon joining the board, Dr. Oesterle remarked, “I am excited to be part of Phagenesis at this pivotal moment. The company has established a robust clinical foundation and is focused on fulfilling significant unmet needs in patient care.” His focus aligns with Phagenesis's commitment to address the challenges posed by severe dysphagia—a swallowing disorder commonly associated with strokes—while also reducing costs and streamlining healthcare processes.

Transitioning Toward Broader Adoption

Phagenesis is building a strong momentum in the U.S. market, driven by increasing recognition of its device, the Phagenyx® System, which utilizes pharyngeal electrical stimulation (PES) to restore safe swallowing. The recent endorsement from the American Heart Association/American Stroke Association has reinforced PES’s role as a clinically validated therapy, showcasing its potential to significantly improve swallowing outcomes and minimize complications in stroke survivors.

Phagenyx®: A Leading Solution

The Phagenyx® System marks an innovative milestone in treating severe post-stroke dysphagia, targeting neurological impairments that disrupt swallowing. In the U.S., it's approved for use in severe dysphagia cases, while it also possesses CE marking in Europe for treating neurogenic dysphagia stemming from various neurological conditions. Phagenesis is backed by top healthcare investors including EQT Life Sciences and others, ensuring investor confidence as it pursues its growth objectives.

Looking Forward

“Steve’s addition to our board comes at a transformation point for Phagenesis,” noted Chad Hoskins, Chief Executive Officer. “As we advance from early commercialization to broader adoption, his expertise in scaling innovative medical technologies will be crucial in enhancing our U.S. growth, deepening clinical acceptance, and establishing Phagenyx as a standard care protocol.”

The integration of Dr. Oesterle’s experience signals a promising direction for Phagenesis as it aims to expand its reach and efficacy in the medical technology field, ultimately prioritizing patient health and wellness.

For more information on Phagenesis and its groundbreaking work in swallowing disorders, please visit Phagenesis.com.